These findings indicated a possible role of increased activation of the PI3K/Akt/mTOR pathway in the chemotherapy resistance observed in our resistant BL cells suggesting that targeting this pathway may be therapeutically relevant in BL. This evidence concerns the gene MTOR and Burkitt lymphoma.